Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Debt-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Debt-to-Asset of 0.01 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Debt-to-Asset too high?
GlaxoSmithKline Pakistan's current Debt-to-Asset is 0.01. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Debt-to-Asset compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Debt-to-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Debt-to-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₨349.04, compared to a current price of ₨314.64 — trading 9.9% below its estimated fair value. The current Debt-to-Asset is 0.01. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Debt-to-Asset is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be undervalued.
The current stock price of ₨314.64 is trading 9.9% below its estimated GF Value™ of ₨349.04.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Undervalued.
Key valuation signals for KAR:GLAXO:
Debt-to-Asset: 0.01
GF Value™: ₨349.04 vs. price of ₨314.64 (9.9% below fair value)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
